An investigational once-weekly pill kept HIV suppressed as effectively as daily treatment over 48 weeks in two phase 3 trials, results that could eventually give people living with HIV an alternative to taking medication every single day.
The single tablet combines 2 milligrams of islatravir, made by Merck, with 300 milligrams of lenacapavir, made by Gilead Sciences. Detailed results from the ISLEND-1 and ISLEND-2 trials were presented at the 26th International AIDS Conference in Rio de Janeiro on July 29, with ISLEND-1 published simultaneously in the New England Journal of Medicine.
